drug and therapy bulletin - hpspc.inhpspc.in/pdf/issue11_drug_therapy.pdf · 12th national...

H.P. STATE

COUNCIL

DRUG AND THERAPYBULLETIN

HIMACHAL PRADESH STATE PHARMACY COUNCIL

Toll Free 18001210443

DRUG INFORMATION CENTER

LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]

Contents |

Drug Updates |

Pharma News |

Examinations |

12th National Convention of Pharmacists |

Drug Information Center |

Issue: 11 ● Volume: 2 ● Aug 2018

DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,

Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]

2

DRUG AND THERAPY BULLETIN

Content

EDITORIAL

Patron

Mr. Gopal Krishan Sharma and Dr. Ran Singh

Editor-in-chief

Dr. Kamlesh Naik and Dr. M.S. Ashawat

Co-Editors

Dr. Vinay Pandit and Mr. Ankush Sharma

Advisory Board

Dr. Navneet Marwah, Mr. Sanjeev Pandit, Dr. Manoj Kumar, Dr. Ranjit Singh, Prof. CPS Verma, Dr. Poonam Sandhu, Dr. Rajender Guleria,

Mr. Arvind Kumar, Mr. Bihari Lal Gupta, Mr, Hemant Sharma, Mr. Rakesh Chandel, Mr. Praveen Upadhya, Mr. Kamashwar Chauhan, Mr.

Lokesh Kumar, Mr. Vishal Kumar, Mr. Y.S.Chandel, Mr. Birbal Sharma, Mr. Manoj Kumar, Mr. Yogesh Verma, Mr. Surender Nadda,

Dr. Parshuram

Drug Updates. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3

Pharma News . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7

Himachal Pradesh Pharmacist (Allopathy) Examination. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

12th National Convention of Pharmacists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

3

DRUG UPDATES



Mulpleta for Thrombocytopenia

âOn August 1, 2018, the US FDA approved Mulpleta

(lusutrombopag) oral tablets indicated to treat

thrombocytopenia in adult patients with chronic liver

disease who are scheduled to undergo a procedure.

Mulpleta, a small molecule thrombopoietin receptor

agonist administered once daily, demonstrated efficacy

in 3 clinical trials in which clinically significant primary

and secondary endpoint results were achieved.

Prescribing information can be found at: https://www.

accessdata.fda.gov/drugsatfda_docs/label/2018/2109

23s000lbl.pdf

Azedra for rare adrenal Tumors

âOn July 30, 2018, the US FDA approved Azedra

(iobenguane I 131) IV injection indicated to treat adult

and pediatric patients 12 years of age or older with

iobenguane scan positive, unresectable, locally advanced

or metastatic pheochromocytoma or paraganglioma who

require systemic anticancer therapy. Azedra, which is the

first drug to gain FDA approval for this use, demonstrated

efficacy in a clinical trial in which a significant number of

patients treated with the drug achieved the primary

endpoint (a 50% or greater reduction of all anti-

hypertensive medication for at least 6 months) and the

secondary endpoint (overall tumor response).



07s000lbl.pdf

Long acting SubQ Perseris for Schizophrenia

On July 27, 2018, the US FDA approved Perserisä

(risperidone) subQ extended-release injection indicated

for the treatment of schizophrenia in adult patients.

Perseris, which is the first once-monthly subQ long-

acting injectable to gain FDA approval, was designed to

achieve clinical risperidone levels after the initial

injection without the need to administer a loading dose or

supplemental oral risperidone. Its efficacy was

demonstrated in a clinical trial in which improvement in

the primary endpoint, Positive and Negative Syndrome

Scale total score at day 57, was achieved.

Pr e s c r i b i n g i n f o rma t i on can be f ound a t :

www.indivior.com/wp-content/uploads/2018/07/FDA-

Label-revised.pdf

Orilissa for Endometriosis

On July 24, 2018, the US FDA approved Orilissaä

(elagolix) oral tablets indicated for the management of

moderate to severe pain associated with endometriosis.

Orilissa, the first oral gonadotropin-releasing hormone

antagonist for endometriosis to gain FDA approval in

more than 10 years, demonstrated efficacy in 2 clinical

trials in which the 3 most common types of

endometriosis pain (ie, daily menstrual pelvic pain, non-

menstrual pelvic pain, and pain with sex) were

significantly reduced in women treated with elagolix

compared with those treated with placebo.



50s000lbl.pdf

Krintafel to prevent Malaria relapse

On July 20, 2018, the US FDA approved Krintafel

(tafenoquine) oral tablets indicated for the radical cure

(prevention of relapse) of Plasmodium vivax malaria in

patients 16 years of age or older who are receiving

appropriate antimalarial therapy for acute P. vivax



4


infection. The first single-dose drug to gain FDA approval

to prevent malaria relapse, Krintafel demonstrated safety

and efficacy in 3 clinical trials and was granted a tropical

disease priority review.



95s000lbl.pdf

Tibsovo for AML with IDH1 mutation

âOn July 20, 2018, the US FDA approved Tibsovo

(ivosidenib) oral tablets indicated to treat adult patients

with relapsed or refractory acute myeloid leukemia

(AML) with a susceptible isocitrate dehydrogenase-1

(IDH1) mutation as detected by an FDA-approved

companion diagnostic test. Tibsovo, the first IDH1

inhibitor to gain FDA approval, demonstrated efficacy in

a clinical trial in which a significant percentage of

ivosidenib-treated patients with AML with an IDH1

mutation experienced complete remission with full or

partial hematologic recovery.

The FDA also approved the RealTime IDH1 Assay, the

companion diagnostic test which detects the IDH1

mutation in blood or bone marrow samples.



92s000lbl.pdf

Zomacton and 4 new indications

âOn July 19, 2018, the US FDA approved Zomacton

(somatropin, e-coli derived) subQ injection for 4

additional pediatric indications: idiopathic short stature

(ISS), short stature associated with Turner syndrome,

short stature born small for gestational age (SGA) with no

catch-up growth by 2 to 4 years, and short stature or

growth failure in short stature homeobox-containing

gene (SHOX) deficiency. Zomacton was initially

marketed to treat growth failure in pediatric patients due

to inadequate secretion of endogenous growth hormone

(GH) and replacement of endogenous GH in adult

patients with GH deficiency. In addition to these

âindications gaining FDA approval, a new ZOMA-Jet

Needle Free Delivery Device for Zomacton will be

launched in September 2018.



17s048s049s050s051lbl.pdf

Kisqali expands use via new FDA pilot programs

On July 18, 2018, the US FDA approved Kisqali

(ribociclib) oral tablets in combination with an aromatase

inhibitor for the treatment of pre/perimenopausal or

postmenopausal women with hormone receptor (HR)-

positive, human epidermal growth factor receptor 2

(HER2)-negative advanced or metastatic breast cancer,

as initial endocrine-based therapy. The FDA also

approved Kisqali in combination with fulvestrant for the

treatment of postmenopausal women with HR-positive,

HER2-negative advanced or metastatic breast cancer, as

initial endocrine based therapy or following disease

progression on endocrine therapy. Kisqali is the first drug

granted approval as part of two new pilot programs, Real-

Time Oncology Review and Assessment Aid, that

collectively aim to make the development and review of

cancer drugs more efficient, while improving FDA's

rigorous standard for evaluating efficacy and safety.


pharma.us.novartis.com/sites/www.pharma.us.novartis

.com/files/kisqali.pdf

Symtuza for HIV-1 Infection

On July 17, 2018, the US FDA approved Symtuzaä

(cob ic i s ta t /darunav i r /emtr ic i tab ine / teno fov i r

alafenamide) oral tablets indicated to treat human

5



immunodeficiency virus type 1 (HIV-1) infection in

treatment-naive and certain virologically suppressed

adults. Symtuza, which is the first and only complete

darunavir-based single-tablet regimen to gain FDA

approval, demonstrated efficacy and safety in the

AMBER and EMERALD studies.

Prescribing information can be found at: http://www.

janssenlabels.com/package-insert/product-monograph/

prescribing information/SYMTUZA-pi.pdf

Xtandi now for non-metastatic CRPC

On July 13, 2018, the US FDA approved an expanded

âindication for Xtandi (enzalutamide) oral capsules for

castration-resistant prostate cancer (CRPC) to include

men with non-metastatic CRPC. Xtandi, which is now

the first and only FDA-approved oral drug for both

metastatic and non-metastatic CRPC, showed a

significantly reduced risk of developing metastasis or

death in men with non-metastatic CRPC when

administered with androgen deprivation therapy (ADT)

compared with ADT alone in the PROSPER clinical trial.

The prescribing information can be found at: https://

www.accessdata.fda.gov/drugsatfda_docs/label/2018/

203415s014lbl.pdf

TPOXX for smallpox treatment

âOn July 13, 2018, the US FDA approved TPOXX

(tecovirimat) oral capsules indicated for the treatment of

human smallpox disease caused by variola virus in adults

and pediatric patients weighing at least 13 kg. Approved

to address the risk of bioterrorism, TPOXX was granted

approval under fast track, priority review, and orphan

drug designations. TPOXX, which is the first drug

approved for this indication, demonstrated increased

survival in animals compared with placebo.

The prescribing information can be found at: https://

www.accessdata.fda.gov/drugsatfda_docs/label/2018/

208627s000lbl.pdf

FDA: Several Valsartan Products recalled for NDMA

On July 13, 2018, the US FDA announced a voluntary

recall of several valsartan-containing products due to an

impurity, N-nitrosodimethylamine (NDMA), which was

found in the recalled products. Classified as a probable

human carcinogen, NDMA was unexpected in these

products and thought to be related to variations in the

manufacturing of valsartan. The FDA will continue to

review this recall to investigate the NDMA levels, assess

the possible effect on patients, and determine measures

that can be taken to reduce or eliminate this impurity in

the future.

Healthcare professionals and patients should access the

following FDA website to determine which valsartan-

containing products are affected by this recall:

https://www.fda.gov/Drugs/DrugSafety/DrugRecalls/def

ault.htm

Opdivo plus Yervoy: New indication

On July 11, 2018, the US FDA approved an additional

âindication for Opdivo (nivolumab) IV injection given in

âcombination with Yervoy (ipilimumab) IV injection for

the treatment of microsatellite instability high (MIS-H) or

mismatch repair deficient (dMMR) metastatic colorectal

cancer (mCRC) that has progressed following treatment

with a fluoropyrimidine, oxaliplatin, and irinotecan in

adult and pediatric patients 12 years and older. The

combination of Opdivo and Yervoy becomes the first

immuno-oncology combination approved for MSI-

H/dMMR mCRC patients that have received the

aforementioned therapy. The two drugs, nivolumab and

ipilimumab, are now approved to treat 3 tumor types.

The accelerated approval was based on data from an



6


ongoing trial that demonstrated clinically significant

results in overall response rate and duration of response.



54s063lbl.pdf and https://www.accessdata.fda.

gov/drugsatfda_docs/label/2018/125377s096lbl.pdf

FDA: Fuoroquinolones and hypoglycemia and mental health ADRs

On July 10, 2018, the US FDA issued a safety

communication regarding systemic fluoroquinolones and

the potential for hypoglycemia, including cases resulting

in coma, as well as certain mental health adverse effects

(ADRs). The mental health ADRs include disturbances in

attention, disorientation, agitation, nervousness,

memory impairment, and delirium. The FDA is requiring

updates to the prescribing information and medication

guides for the entire fluoroquinolone class (i.e.,

ciprofloxacin, ciprofloxacin hydrochloride, delafloxacin,

gemifloxacin, levofloxacin, moxifloxacin, and ofloxacin).

Xeomin for excessive salivation

On July 3, 2018, the US FDA approved a new indication

âfor Xeomin (incobotulinumtoxinA) intraglandular

injection for treatment of chronic sialorrhea in adult

patients. Xeomin is the first and only neurotoxin

approved for this indication. Approval was based on a

clinical trial that demonstrated significant improvement

in change in unstimulated salivary flow rate and Global

Impression of Change Scale at week 4 compared with

placebo.



60s073lbl.pdf

New Aripiprazole Lauroxil Regimen

On July 2, 2018, the US FDA approved Aristada Initioä

(aripiprazole lauroxil) extended-release injection

suspension, in combination with oral aripiprazole, for the

âinitiation of Aristada when used for the treatment of

schizophrenia in adults. This approval makes Aristada

the first and only long-acting atypical antipsychotic that

can be initiated on day 1 and provides up to 2 months of

treatment. Although Aristada Initio and Aristada both

contain aripiprazole lauroxil, they are not inter-

changeable due to their differing pharmacokinetic

profiles. Aristada Initio carries a black box warning of

increased mortality in elderly patients with dementia-

related psychosis.


aristadahcp.com/downloadables/ARISTADA-INITIO-

PI.pdf

Reference: www.micromedexsolutions.com

7



PHARMA NEWS

Strict regulatory action to prevent illegal manufacturing, sale, distribution and import of oxytocin in India

The ministery of health and family welfare has issued

notification which will come into effect from

01-09-2018, to regulate and restrict the manufacture,

sale and distribution of oxytocin in following manner:

1) The manufacture of oxytocin formulation for domestic

use shall be by public sector undertaking or companies

only and label of product shall bear barcode.

2) The manufacture of oxytocin formulations for export

purposes shall be open to both public and private

sector companies and pack of such manufacture of

exports shall bear barcodes.

3) The manufactures of active pharmaceutical

ingredient (API) shall supply the API only to the

public sector manufacturers licensed under drugs

and cosmetics rules, 1945 for manufacture of

formulation of said drug for domestic use.

4) The manufacturers of active pharmaceutical

ingredient of oxytocin shall supply the said active

pharmaceutical to the manufacturers in public and

private sector licensed under drugs and cosmetic

rules, 1945 for manufacture of formulation of said

drug for export purpose.

5) Oxytocin formulations manufactured by the public

sector companies or undertaking licensed under the

drugs and cosmetic rules, 1945 for domestic use

shall supply the formulations meant for human and

veterinary use only –

¨ To the registerd hospitals and clinics in public

and private sector directly.

¨ To Pradhan Mantri Janaushadhi Pariyojna and

Affordable Medicines and Reliable Implants for

treatment outlets or any other Govt. entity which

may be specified by the central Govt. which shall

further supply the drug to registered hospitals

and clinics in public and private sector.

6) The oxytocin in any form or name shall not be

allowed to be sold through retail chemist.

The issue is being discussed and monitored at highest

level of Govt. from time to t ime for proper

implementation of various measures taken to prevent

misuse of the drug in the country.

Ref: www.cdsco.nic.in

EMA restricts use of prostate cancer medicine Xofigo

The European Medicines Agency (EMA) has concluded

its review of the cancer medicine Xofigo (radium-223

dichloride), and has recommended restricting its use to

patients who have had two previous treatments for

metastatic prostate cancer (prostate cancer that has

spread to the bone) or who cannot receive other

treatments. Xofigo must also not be used with the

medicines Zytiga (abiraterone acetate) and the

corticosteroid prednisone or prednisolone. Xofigo should

not be used with other systemic cancer therapies, except

for treatments to maintain reduced levels of male

hormones (hormone therapy). The medicine should also

not be used in patients who have no symptoms, in line

with the current indication; in addition, the use of Xofigo

is not recommended in patients with a low number of

bone metastases called osteoblastic bone metastases.

Ref: www.pharmatutor. org

Onpattro: New medicine for hereditary rare disease

The European Medicines Agency's (EMA) Committee for

Medicinal Products for Human Use (CHMP) has



8


recommended granting a marketing authorisation for

Onpattro (patisiran), for the treatment of hereditary

t rans thyre t in -media ted amylo idos is (hATTR

amyloidosis) in adult patients with stage 1 or stage 2

polyneuropathy (a condition in which the peripheral

nerves are damaged). This medicine is expected to affect

the course of the disease and improve patient functioning

and quality of life.

Ref: www.pharmatutor. org

Cannabis and related drugs can harm your brain

Long-term use of either cannabis or cannabis-based drugs

impairs memory say researchers. The study has

implications for both recreational users and people who use

the drug to combat epilepsy, multiple sclerosis and chronic

pain. They found that mice exposed to the drug long-term

had “significant ... memory impairments” and could not

even discriminate between a familiar and novel object.

There is little understanding of the potential negative side

effects of long-term cannabinoid exposure, though it is

already known that heavy, regular cannabis use

increases the risk of developing mental health problems

including psychosis and schizophrenia.

Ref: www.pharmatutor.org

New IgM antibody found effective against HIV

San Antonio, Texas A group of scientists at Texas

Biomedical Research Institute have zeroed in on a new

defense against HIV-1, the virus that causes AIDS. Led

by Ruth Ruprecht, M.D., Ph.D., the team used an animal

model to show for the first time that an antibody called

Immunoglobulin M (IgM) was effective in preventing

infection after mucosal AIDS virus exposure. The IgM

antibody has multiple arms to catch the virus, making it

more efficient in clumping up the virus and keeping it

from passing through the mucosal barrier and entering

the rest of the body.


Cabinet approves MoU between India and Indonesia in the field of pharmaceutical products, pharmaceutical substances, biological product and cosmetics regulatory functions

The Union Cabinet chaired by the Prime Minister Shri

Narendra Modi has given its ex-post facto approval for

the Memorandum of Understanding (MoU) between the

Central Drugs Standard Control Organization (CDSCO),

India and National Agency for Drug and Food Control

(BPOM), Indonesia on cooperation in the field of

pharmaceutical products, pharmaceutical substances,

biological product and cosmetics regulatory functions.

The MoU was on signed on 29th May, 2018 in Jakarta.

The CDSCO is a Subordinate Office of the Directorate

General of Health Services, which is an attached office of

the Department of Health and Family Welfare and is the

National Regulatory Authority for drugs, medical devices

and cosmetics in India.



9

The MoU is expected to forge better understanding about

each other's regulatory requirements and would be

beneficial to both the countries. It could also facilitate

India's export of pharmaceutical products. It will also

establish a framework for fruitful cooperation and

exchange of information between the two countries in

matters relating to Pharmaceutical products regulation

on the basis for equality, reciprocity and mutual benefit.

Further, it will facilitate better understanding between

the regulatory authorities of the two countries.


Cabinet approves MoU between India and Cuba in the field of Traditional Systems of Medicine and Homeopathy

The Union Cabinet chaired by Prime Minister Shri

Narendra Modi has given its ex-post facto approval for

the Memorandum of Understanding (MoU) between

India and Cuba on cooperation in the field of Traditional

Systems of Medicine and Homeopathy. The MoU was

signed on 22-6-2018. The MoU will enhance bilateral

cooperation between the two countries in the areas of

Traditional Systems of Medicine and Homeopathy.

This will be of immense importance to both countries

considering their shared cultural heritage.


Drug regulator cancels licence for Diclofenac sold by Novartis

India's drug regulator has enforced a ban on the

manufacture and sale of painkiller injection, Diclofenac,

marketed by Novartis India Ltd, after a Health Ministry

panel raised concerns over the medicine's impact on

health. The drug controller general of India (DCGI)

further ordered for the withdrawal of the drug's stock

from the market. Diclofenac injection was marketed by

Novartis under the brand name Voveran 1ml.

Ref: www.healtheconomics.indiatimes.com

Reducing the length of the antibiotic course reduces the risk of resistance

Treatments using antibiotics should stop as soon as

possible to prevent patients passing the “tipping point” of

becoming resistant to their effects, new research has

shown. A team of researchers has uncovered new

evidence that suggests reducing the length of the

antibiotic course reduces the risk of resistance. They

found that changes both in the duration and dose of

antibiotics used and in sugar levels (which mimics the

variable sugar levels in human patients) could push

these microbial communities beyond a “tipping point” –

creating an irreversible shift to becoming drug resistant.


Acetazolamide found effective in glioblastoma

A drug used to treat altitude sickness – as well as

glaucoma, epilepsy, heart failure and seizures – may also

offer significant gains for patients with a fast-growing

brain tumor known as glioblastoma, according to a study.


NPPA fixes prices of 58 drug formulations

The national drug pricing regulator NPPA has fixed the

retail and ceiling prices of 58 formulations used for

treatment of various ailments, including cardiac

conditions, anxiety disorders, Hepatitis C and diabetes.

While the National Pharmaceutical Pricing Authority

(NPPA) has fixed the retail prices of 56 formulations, it

has also capped the ceiling prices of two formulations, a

notification on the regulator's website said. The prices

have been fixed/revised under the Drug (Prices Control)




10

Order, 2013, it added. The regulator has fixed the retail

prices of drugs manufactured and marketed by various

firms. The drugs include Sofosbuvir and Ledipasvir tablets

used for treatment of hepatitis C. It has also fixed the retail

price of Teneligliptin Metformin tablet (Teneblu M Forte)

used for treatment of diabetes. The NPPA has capped the

ceiling prices of Digoxin and Furosemide oral liquids.


Wisconsin man had his lower legs and hands

Aamputated after developing a rare blood

infection caused by bacteria in dog saliva.

He first developed flu-like symptoms such as fever

and vomiting. By the next morning, his temperature

had soared and he was delirious. After his wife

rushed him to the hospital, she noticed his body was

covered in bruises, as if he'd been beaten with a

baseball bat, the Washington Post reported.

Within a week, Manteufel's legs were amputated

from the knees down. Then doctors had to remove his

hands. Doctors diagnosed Manteufel with a rare

blood infection caused by bacteria called

Capnocytophaga canimorsus that’s commonly found

in the saliva of most healthy dogs and is usually not

harmful to humans, the Post reported. But in

Manteufel’s case, the bacteria got into his

bloodstream, triggering blood poisoning (sepsis). The

bruises on his body were actually blood spots caused

by the sepsis.Manteufel was given antibiotics to fight

the infection, but clots blocked blood flow to his

extremities, resulting in tissue and muscle death and

the need to amputate his legs and hands in order to

save his life, the Post reported.

Greg Manteufel loves dogs and had been around eight

of them about the time he became ill, according to his

wife Dawn Manteufel. It's not clear which dog was

carrying the bacteria. She told the Post that doctors

said her husband's case was a “crazy fluke.”

Greg Manteufel has been at Froedtert Hospital & the

Medical College of Wisconsin in Milwaukee for about

a month. He recently had surgery to remove dead

tissue and muscle from his leg amputations. This

week, he will have two more surgeries to remove

dead tissue, the Post reported. He may also require

nose reconstruction surgery because lack of blood

flow caused it to turn black, his wife said.

By: Manoj Sharma, Registered Pharmacist.

Amputation due to dog salivaAmputation due to dog saliva



11

EXAMINATIONS

HP Pharmacist (Allopathy) Exam

Those candidates who submitted the application form

under the advertisement No. 33-2/2017, for the post of

pharmacist (Allopathy), Post code- 586 in prescribed

format, can get the admit card from HPSSSB Hamirpur

site www.hpsssb.hp.gov.in.

Admit card is not issued to such candidates who fail to

submit the application fee. The exam will be held on

19-08-2018 in the morning session.

12th National Convention of Pharmacists

All Pharmacists including Hospital / Chemist / Druggist / Teachers/Marketing Representatives / working in

companies are hereby invited to attend inaugural ceremony of 12th National Convention of Pharmacists at

Laureate Institute of Pharmacy Kathog on 11-08-2018. Chief Guest for the function is Hon’ble Health Minister

Sh. Vipin Parmar Ji and Chairman of function is Dr. (Prof.) B. Suresh, President, PCI.

Registeration Fee: Rs. 300/- (only for inaugural session)

Rs. 4000/- (Including all days scientific session/Cultural Program/Accomodation, etc.)

NATIONAL CONVENTION




12

Which kind of queries can be asked from Drug

Information Center?

It is the matter of pride for all the population of Himachal

Pradesh that there is drug information center (DIC) in the

state which is giving the services to promote the rational

drug use. Maximum population of state knows that there is

DIC, but they are unaware about the services of the DIC.

They all are confused that which kind of queries they can ask.

There is no any restriction to take the drug query

information by any one. Any person (physician, pharmacist,

nurse, patient, people of community, old persons, students,

researchers etc.) can come in or call in the DIC office to take

drug information.

Following kinds of queries regarding drugs can be asked

from DIC:

Ÿ If patient is administering two medicines at the same

time then he/she before administering the medicine,

can confirm from DIC that this combination is safe or not

safe. If combination will be not safe then it may also be

life threatening.

Ÿ If patient is administering a medicine then he/she can

confirm which kinds of foods have to be avoided.

Ÿ Someone can confirm that use of any specific medicine

in particular condition (like as pregnancy/lactation) is

safe or not safe.

Ÿ General information about drug identification can also

be taken from the DIC, like as use and side/adverse

effects , t ime of administrat ion, durat ion of

administration, dose in different age groups etc. about

any drug.

Ÿ Information about substituted drugs with different

prices can also be provided by DIC.

Ÿ Any updation about medicines can be confirmed from

DIC.

DIC will provide the accurate information on request

without any fear and favor. In short, we can say that DIC can

provide any kind of information about any medicine to

anyone without any cost. Personnel can assess directly, can

call in the DIC office, sent the query by post, by E-mail

Toll Free 18001210443, Phone: 09218428042, 9459220253

Scan this Quick Response (QR)

code to know more

You may download any QR code scanner from

Play Store/iTunes

Personnel can assess directly, can call in the DIC office, sent the query by post, by E-mail on following address.

Note: If any want to publish his/her article in the monthly bulletin of Drug Information Center regarding Pharma updates, they can send their articles with their full address and professional status on the following reference before 25th of every month.

Toll Free 18001210443

DRUG INFORMATION CENTER

HIMACHAL PRADESH STATE PHARMACY COUNCIL

Laureate Institute of Pharmacy, Kathog, Jwala Ji, Distt. Kangra HP 177101

Website: www.hpspc.in | Mail ID: [email protected], [email protected]©

2018, Pharm

a P

uls

e |

info

@pharm

apuls

e.in

drug and therapy bulletin - hpspc.inhpspc.in/pdf/issue11_drug_therapy.pdf · 12th national...

Documents